99.9 % of people’s genes are identical. Exploring the unique information held in the last 0.1% has initiated one of the most exciting and promising trends in healthcare today – precision medicine.
Since the cost of genome sequencing went from $2.7B to less than that of an average chest X-ray, the use of big data analytics in healthcare is on a rapid path to becoming mainstream. The convergence of genome sequencing and data analytics is impacting clinical care today, but there are still obstacles to overcome before precision medicine shifts completely from research to reality.
Join Johnson & Johnson Innovation, JLABS as we explore the “digital genomics” landscape, addressing topics including:
- Tackling the massive amounts of phenotypic and genomic data
- Using this information to drive effective therapies
- The impact of “digital genomics” on healthy people
Kelly Frazer | Director, UCSD Institute for Genomic Medicine & Founding Chief, Division of Genome Information Sciences, Department of Pediatrics, UCSD read bio»
Alexander Grunewald | Global Head - Healthcare Innovation Strategy, Johnson & Johnson Innovation read bio»
Razelle Kurzrock, MD | Medical Advisor & Co-Founder, CureMatch, Inc. Sr. Deputy Center Director, Clinical Science; Director, Center for Personalized Cancer Therapy, UCSD Moores Cancer Center read bio»
Erica Ramos | Staff Genetic Counselor, Illumnia read bio»
Lucian Iancovici | Sr. Investment Manager, Qualcomm Life Fund read bio»
3:00 PM | Registration Opens, Networking
3:30 PM | Panel Discussion
4:30 PM | Networking & Refreshments
5:00 PM | Program Close
Who should attend:
Digital health companies and startups, entrepreneurs, advisors & investors.
$35 | General Public
$20 | Student/Academic
$45 | At the door
3210 Merryfield Row
San Diego, CA
Kelly Frazer Ph.D. | Director, UCSD Institute for Genomic Medicine & Founding Chief, Division of Genome Information Sciences, Department of Pediatrics, UCSD
Dr. Frazer is a professor and the founding chief of the Division of Genome Information Sciences in the Department of Pediatrics, Director of UC San Diego’s Institute for Genomic Medicine and a leader at the university’s Clinical and Translational Research Institute. Prior to joining UCSD in 2009, Dr. Frazer was Professor of Translational Genomics at the Scripps Research Institute and, previously, Vice President of Genomic Biology at Perlegen Sciences. Dr. Frazer has spent the past 25 years studying various aspects of functional and structural human genomics, and her contributions include pioneering cross-species DNA sequence comparisons between humans and mice, generating the content now publicly available in the “HapMap Phase II,” and developing novel methods for identifying and functionally annotating variants underlying GWAS signals. Dr. Frazer’s current research studies are supported by the National Institutes of Health, the K.G. Jebsen Medical Foundation, the California Institute for Regenerative Medicine as well as industry and cross-institutional collaborations.
Alexander Grunewald, Ph.D. | Global Head - Healthcare Innovation Strategy, Johnson & Johnson Innovation
Alexander leads external innovation in Health Solutions and Digital Health at Johnson & Johnson. His team's focus areas include improving patient outcomes, enhancing wellness of healthy consumers, driving R&D operational advances, and exploring digital therapeutics and genomics. Alexander began his career in academia, first as a senior postdoctoral scholar in neuroscience at the California Institute of Technology and then as an assistant professor at the University of Wisconsin-Madison. During that time he was published in numerous important research articles, led a visual neurophysiology research team, and taught neuroscience to undergraduate and graduate students. He then transitioned into industry where he led client engagements in strategy, sales and operations for healthcare companies as a health care leader at McKinsey & Company in Los Angeles. From there he transitioned to running the Drug Compare business at DestinationRx, Inc., a healthcare IT company. He also served as senior director of corporate strategy and business development at McKesson. In this role, he led his team to define the strategy and M&A for the company's U.S. Pharma and Specialty businesses. Alexander has a Ph.D. in Computational Neuroscience from Boston University and a B.Sc. in Mathematics from King's College in London, England.
Connect with Alexander:
Razelle Kurzrock, MD | Medical Advisor and CoFounder, CureMatch, Inc. Sr. Deputy Center Director, Clinical Science Director, Center for Personalized Cancer Therapy Director, Clinical Trials Office Team Leaders, Experimental Therapeutics UCSD Moores Cancer Center Chief, Division of Hematology and Oncology, UCSD School of Medicine
Dr. Razelle Kurzrock is co-founder and medical advisor of CureMatch, Inc., a San-Diego based digital health company focusing on precision medicine in oncology using combination therapies.
Dr. Kurzrock is known for devloping the largest Phase 1 clinical trials department in the nation/world while at the University of Texas, M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.
At Moores Cancer Center, Dr. Kurzrock's charge is broad, including not just growing and innovating the center's clinical trials program, but also heading its newly establsihed Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system.
Dr. Kurzrock received her MD degree from the University of Toronto and has over 650 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase 1 program building. Dr. Kurzrock also has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigatinoal Cancer Therapeutics. At UCSD Moores Cancer Center, she founded and directs the Fellowship in Personalized Cancer Therapy. Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.
Erica Ramos | Clinical Head, Healthy Genome Initiatives; Staff Genetic Counselor, Applied Genomics, Illumina
Erica Ramos, MS, LCGC is the clinical lead for Illumina’s “Healthy Genome Initiatives” team and is the 2017 President-Elect for the National Society of Genetic Counselors, the leading professional organization for genetic counselors more than 3500 members strong. After 11 years in patient care, Ms. Ramos joined Illumina in the Clinical Services Laboratory, where she managed the clinical group that implemented interpretation and reporting processes for clinical whole genome sequencing (cWGS). Currently, she focuses on advancing the use of cWGS by providing access and education to healthy individuals through the Understand Your Genome program, MyGenome visualization software and other collaborations. Her focus on education extends to genetic counseling students and she is an Adjunct Professor in the Genetic Counseling Department at Augustana University. She also tweets from @ERamosSD about genomics and genetic counseling, music, Wisconsin sports and other interests.
Connect with Erica:
When & Where
JLABS San Diego
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.